A Phase 4 interventional study of Budesonide/formoterol (Symbicort® Turbuhaler®) and Tiotropium (SpirivaTM) in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 30 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-03-27.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 47th largest by enrollment of the 194 interventional ones that give a count, is one of 28 that started in 2011, is one of 19 in phase 4, and was the 101st registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 28 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 793 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with severe chronic obstructive pulmonary disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Add-on treatment
Drug: Budesonide/formoterol (Symbicort® Turbuhaler®) · Drug: Tiotropium (SpirivaTM)
Add-on treatment
Drug: Tiotropium (SpirivaTM)
Drug page: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
Pre-dose FEV1
Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value
Time frame: Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug
Post-dose FEV1 at 5 Minutes
Ratio of post-dose FEV1 at 5 minutes to baseline value
Time frame: Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug
Post-dose FEV1 at 60 Minutes
Ratio of post-dose FEV1 at 60 minutes to baseline value
Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Pre-dose FVC
Ratio of pre-dose FVC (Forced Vital Capacity) in treatment period to baseline value
Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Post-dose FVC at 5 Minutes
Ratio of post-dose FVC at 5 minutes to baseline value
Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)
Post-dose FVC at 60 Minutes
Ratio of post-dose FVC at 60 minutes to baseline value
Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Pre-dose IC
Ratio of pre-dose IC (Inspiratory Capacity) in treatment period to baseline value
Time frame: Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug
Post-dose IC at 60 Minutes
Ratio of post-dose IC at 60 minutes to baseline value
Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Pre-dose PEF in Last Week of Treatment
Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment, up to 12 weeks
Pre-dose PEF in First Week of Treatment
Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to first week of treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the first week of treatment
Pre-dose PEF in Whole Treatment Period
Change in pre-dose morning PEF from run-in period to whole treatment period
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period of 12 weeks
Post-dose PEF in Last Week of Treatment
Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment, up to 12 weeks
Post-dose PEF in First Week of Treatment
Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the first week of treatment
Post-dose PEF in Whole Treatment Period
Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period of 12 weeks
Use of Reliever Medication During Day in the Last Week on Treatment
Change in the number of inhalations of reliever medication during day from run-in period to the last week on treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks
Use of Reliever Medication During Day in the First Week on Treatment
Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment
Use of Reliever Medication During Day in the Whole Treatment Period
Change in the number of inhalations of reliever medication during day from run-in period to the whole treatment period
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks
Use of Reliever Medication During Night in the Last Week on Treatment
Change in the number of inhalations of reliever medication during night from run-in period to the last week on treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks
Use of Reliever Medication During Night in the First Week on Treatment
Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment
Use of Reliever Medication During Night in the Whole Treatment Period
Change in the number of inhalations of reliever medication during night from run-in period to the whole treatment period
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks
Change in COPD Symptoms - Breathing
Change in breathing symptom score (from 0:none to 4:severe) from run-in period
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks
Change in COPD Symptoms - Cough
Change in Cough symptom score (from 0:none to 4:severe) from run-in period
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks
Change in COPD Symptoms - Sputum
Change in Sputum symptom score (from 0:none to 4:severe) from run-in period
Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks
COPD Exacerbations
Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms
Time frame: Whole treatment period of 12 weeks
There are 793 patients enrolled. 578 patients were randomized, where there are 287 patients randomized in Symbicort+ Spiriva group and 291 in Spiriva group
| Milestone | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Started | 287 | 291 |
| Post-baseline efficacy data collected | 287 | 290 |
| Received correct randomized treatment | 286 | 287 |
| Completed | 264 | 260 |
| Not completed | 23 | 31 |
| Withdrew: Withdrawal by subject | 7 | 11 |
| Withdrew: Eligibility criteria not fulfilled | 7 | 6 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Condition under investigation worsened | 1 | 3 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Severe non-compliance to protocol | 2 | 1 |
| Withdrew: Others | 2 | 1 |
Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Pre-dose FEV1 | 1.050 (1.030 to 1.070) | 1.006 (0.987 to 1.025) |
Ratio of post-dose FEV1 at 5 minutes to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose FEV1 at 5 Minutes | 1.128 (1.109 to 1.147) | 1.045 (1.028 to 1.062) |
Ratio of post-dose FEV1 at 60 minutes to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose FEV1 at 60 Minutes | 1.164 (1.144 to 1.185) | 1.072 (1.053 to 1.091) |
Ratio of pre-dose FVC (Forced Vital Capacity) in treatment period to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Pre-dose FVC | 1.032 (1.017 to 1.047) | 1.013 (0.999 to 1.029) |
Ratio of post-dose FVC at 5 minutes to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose FVC at 5 Minutes | 1.096 (1.081 to 1.110) | 1.044 (1.030 to 1.057) |
Ratio of post-dose FVC at 60 minutes to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose FVC at 60 Minutes | 1.116 (1.100 to 1.132) | 1.059 (1.044 to 1.074) |
Ratio of pre-dose IC (Inspiratory Capacity) in treatment period to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Pre-dose IC | 1.042 (1.017 to 1.068) | 1.022 (0.998 to 1.047) |
Ratio of post-dose IC at 60 minutes to baseline value
| Ratio | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose IC at 60 Minutes | 1.154 (1.129 to 1.180) | 1.087 (1.064 to 1.110) |
Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment
| L/min | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Pre-dose PEF in Last Week of Treatment | 15.753 (7.306 to 24.200) | -4.550 (-13.154 to 4.054) |
Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to first week of treatment
| L/min | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Pre-dose PEF in First Week of Treatment | 13.405 (8.464 to 18.345) | -0.182 (-4.994 to 4.630) |
Change in pre-dose morning PEF from run-in period to whole treatment period
| L/min | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Pre-dose PEF in Whole Treatment Period | 12.271 (6.382 to 18.160) | -5.198 (-10.925 to 0.530) |
Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment
| L/min | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose PEF in Last Week of Treatment | 23.379 (13.199 to 33.560) | -3.049 (-13.556 to 7.458) |
Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment
| L/min | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose PEF in First Week of Treatment | 17.412 (9.349 to 25.476) | 0.220 (-7.486 to 7.926) |
Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period
| L/min | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Post-dose PEF in Whole Treatment Period | 15.880 (9.307 to 22.454) | -2.591 (-9.063 to 3.880) |
Change in the number of inhalations of reliever medication during day from run-in period to the last week on treatment
| times/day | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Use of Reliever Medication During Day in the Last Week on Treatment | -0.750 (-0.935 to 0.566) | -0.082 (-0.267 to 0.103) |
Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment
| times/day | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Use of Reliever Medication During Day in the First Week on Treatment | -0.457 (-0.598 to -0.316) | -0.082 (-0.222 to 0.058) |
Change in the number of inhalations of reliever medication during day from run-in period to the whole treatment period
| times/day | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Use of Reliever Medication During Day in the Whole Treatment Period | -0.685 (-0.836 to -0.533) | -0.134 (-0.284 to 0.016) |
Change in the number of inhalations of reliever medication during night from run-in period to the last week on treatment
| times/day | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Use of Reliever Medication During Night in the Last Week on Treatment | -0.174 (-0.299 to -0.049) | 0.062 (-0.062 to 0.187) |
Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment
| times/day | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Use of Reliever Medication During Night in the First Week on Treatment | -0.113 (-0.206 to -0.019) | 0.011 (-0.081 to 0.104) |
Change in the number of inhalations of reliever medication during night from run-in period to the whole treatment period
| times/day | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Use of Reliever Medication During Night in the Whole Treatment Period | -0.241 (-0.336 to -0.147) | -0.010 (-0.104 to 0.084) |
Change in breathing symptom score (from 0:none to 4:severe) from run-in period
| score on a scale | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Change in COPD Symptoms - Breathing | -0.372 (-0.454 to -0.290) | -0.110 (-0.191 to -0.029) |
Change in Cough symptom score (from 0:none to 4:severe) from run-in period
| score on a scale | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Change in COPD Symptoms - Cough | -0.311 (-0.394 to -0.229) | -0.169 (-0.250 to -0.087) |
Change in Sputum symptom score (from 0:none to 4:severe) from run-in period
| score on a scale | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Change in COPD Symptoms - Sputum | -0.216 (-0.295 to -0.136) | -0.094 (-0.173 to -0.014) |
Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms
| exacerbations/participant/12 weeks | Symbicort+Spiriva | Spiriva |
|---|---|---|
| COPD Exacerbations | 0.182 (0.138 to 0.239) | 0.307 (0.248 to 0.379) |
Collected over 12 weeks of treatment period. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort+Spiriva | — | 14/289 (4.8%) | 75/289 (26%) |
| Spiriva | — | 24/289 (8.3%) | 76/289 (26.3%) |
| Event | Symbicort+Spiriva | Spiriva |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 7/289 | 13/289 |
| PneumoniaInfections and infestations | 2/289 | 4/289 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/289 | 1/289 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/289 | 1/289 |
| H1N1 influenzaInfections and infestations | 0/289 | 1/289 |
| Lower respiratory tract infectionInfections and infestations | 0/289 | 1/289 |
| InfluenzaInfections and infestations | 1/289 | 0/289 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/289 | 1/289 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/289 | 1/289 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/289 | 1/289 |
| Event | Symbicort+Spiriva | Spiriva |
|---|---|---|
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 6/289 | 13/289 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/289 | 7/289 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/289 | 1/289 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 5/289 | 1/289 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 5/289 | 1/289 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 5/289 | 0/289 |
| Upper respiratory tract infectionInfections and infestations | 5/289 | 3/289 |
| Dry mouthGastrointestinal disorders | 3/289 | 4/289 |
| InfluenzaInfections and infestations | 4/289 | 1/289 |
| HeadacheNervous system disorders | 1/289 | 4/289 |
Overall Number of Baseline Participants is not different from the Milestones.
| Age, Continuous(Years) | Symbicort+Spiriva | Spiriva | Total |
|---|---|---|---|
| Mean | 66.6 ± 7.99 | 66.9 ± 8.50 | 66.8 ± 8.25 |
| Sex: Female, Male(Participants) | Symbicort+Spiriva | Spiriva | Total |
|---|---|---|---|
| Female | 8 | 17 | 25 |
| Male | 279 | 273 | 552 |
The record gives a start of Jul 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Pulmonary Disease, Chronic Obstructive →